CD19 and plasma cell myeloma: Other distinct antigens in multiple myeloma include CD19 (the target of most CAR-T therapies in lymphoma), CD38 (the target of daratumumab and isatuximab), CS1/SLAMF7 (the target of elotuzumab), and GPRC5D (the target of the investigational bispecific antibody talquetamab).